Hauger-Klevene J H
Pharmatherapeutica. 1981;3(1):46-54.
The effect of labetalol on blood pressure, heart rate and the renin-angiotensin system was evaluated in 12 patients with severe essential hypertension (diastolic blood pressure greater than or equal to 120 mmHg, WHO: Phase I and II) who had been resistant to other therapeutic regimens. In 9 (76%) patients, labetalol produced a marked reduction in systolic and diastolic pressure (p less than 0.001), while the other 3 patients required the combination of high doses of the drug (1600 mg/day) with a diuretic to achieve normal blood pressure levels. The average dose which controlled blood pressure levels was 777 +/- 393 mg/day. Treatment produced a progressive decrease in heart rate. Side-effects were transient. In contrast to other beta-adrenergic blockers, treatment with labetalol did not modify plasma renin activity levels nor the total concentration of renin or inactive renin levels. During the 1-year follow-up none of the patients treated with labetalol developed cardiovascular accidents, while 4 cardiovascular events occurred in a group of 12 age-matched non-treated severely hypertensive patients. The results of this study indicate that labetalol, administered as a single therapy or in combination with a diuretic, can control blood pressure levels in severely hypertensive patients who had been resistant to the administration of other therapies. Its effects on blood pressure are not related to the renin-angiotensin system.
对12例重度原发性高血压患者(舒张压大于或等于120 mmHg,WHO:I期和II期)进行了研究,评估拉贝洛尔对血压、心率和肾素 - 血管紧张素系统的影响,这些患者对其他治疗方案均耐药。9例(76%)患者使用拉贝洛尔后收缩压和舒张压显著降低(p<0.001),而另外3例患者需要将高剂量药物(1600 mg/天)与利尿剂联合使用才能达到正常血压水平。控制血压水平的平均剂量为777±393 mg/天。治疗使心率逐渐下降。副作用是短暂的。与其他β - 肾上腺素能阻滞剂不同,使用拉贝洛尔治疗并未改变血浆肾素活性水平、肾素总浓度或无活性肾素水平。在1年的随访中,接受拉贝洛尔治疗的患者均未发生心血管意外,而在一组12例年龄匹配的未治疗重度高血压患者中发生了4次心血管事件。本研究结果表明,拉贝洛尔作为单一疗法或与利尿剂联合使用,可控制对其他治疗耐药的重度高血压患者的血压水平。其对血压的影响与肾素 - 血管紧张素系统无关。